Akoya Biosciences, Inc. announced on December 10, 2024, an exclusive global license agreement with NeraCare for the development and commercialization of NeraCare’s Immunoprint test. This agreement will deploy the Immunoprint test on Akoya's multiplexed immunofluorescent platform, specifically the PhenoImager HT.
The Immunoprint assay addresses a critical unmet need by identifying early-stage melanoma patients at high risk of relapse, who are currently ineligible for effective adjuvant therapies. Melanoma sees over 235,000 new diagnoses annually, with 80% in early-stage disease, representing a significant market opportunity for personalized therapy selection.
This partnership expands Akoya's clinical strategy, providing the company and its pharmaceutical partners with an opportunity to transform melanoma patient care. The agreement grants Akoya the exclusive right to develop, market, and commercialize the test for clinical research, diagnostic development, and patient clinical testing following regulatory approval.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.